NurExone Biologic (FRA:J90) Tariff Resilience Score: 6/10 (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J90 NurExone Biologic Inc FRA:J90
40 GF Score
Price €0.31
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Tariff Resilience Score?

NurExone Biologic FRA:J90 40 Tariff Resilience Score is 6 as of Jul. 13, 2026. GuruFocus rates FRA:J90 with a GF Score™ of 40/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, NurExone Biologic ranks better than 75.99% on this metric.

NurExone Biologic has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

NurExone Biologic has NurExone Biologic, a biotech firm, may face tariffs on imported research materials and equipment. However, its niche market and potential for local partnerships provide some resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes NurExone Biologic might have Average Resilient.

NurExone Biologic  (FRA:J90) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

NurExone Biologic Tariff Resilience Score Related Terms

FRA:J90 vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, NurExone Biologic's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Tariff Resilience Score falls into.


FRA:J90
40GF Score
NurExone Biologic Inc FRA:J90
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
NurExone Biologic (FRA:J90) has a Tariff Resilience Score of 6 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, NurExone Biologic ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is NurExone Biologic's Tariff Resilience Score too high?
NurExone Biologic's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. NurExone Biologic's value of 6 is 50% above this industry median. Based on the distribution chart, NurExone Biologic ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NurExone Biologic has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #329 out of 1370 companies for Tariff Resilience Score. This places NurExone Biologic in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. NurExone Biologic's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NurExone Biologic's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NurExone Biologic's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. NurExone Biologic's overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Tariff Resilience Score is 6 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
40GF Score

Get the complete analysis for FRA:J90

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price